Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 82

1.

Composite spheres made of bioengineered spider silk and iron oxide nanoparticles for theranostics applications.

Kucharczyk K, Rybka JD, Hilgendorff M, Krupinski M, Slachcinski M, Mackiewicz A, Giersig M, Dams-Kozlowska H.

PLoS One. 2019 Jul 15;14(7):e0219790. doi: 10.1371/journal.pone.0219790. eCollection 2019.

2.

Plasma lncRNA expression profile as a prognostic tool in BRAF-mutant metastatic melanoma patients treated with BRAF inhibitor.

Kolenda T, Rutkowski P, Michalak M, Kozak K, Guglas K, Ryś M, Galus Ł, Woźniak S, Ługowska I, Gos A, Teresiak A, Mackiewicz A, Lamperska K, Mackiewicz J.

Oncotarget. 2019 Jun 11;10(39):3879-3893. doi: 10.18632/oncotarget.26989. eCollection 2019 Jun 11.

3.

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H, Mandalá M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Nathan PD, Ribas A, Davies MA, Flaherty KT, Burgess P, Tan M, Gasal E, Voi M, Schadendorf D, Long GV.

N Engl J Med. 2019 Jun 4. doi: 10.1056/NEJMoa1904059. [Epub ahead of print]

PMID:
31166680
4.

Oncogenic Role of ZFAS1 lncRNA in Head and Neck Squamous Cell Carcinomas.

Kolenda T, Guglas K, Kopczyńska M, Teresiak A, Bliźniak R, Mackiewicz A, Lamperska K, Mackiewicz J.

Cells. 2019 Apr 21;8(4). pii: E366. doi: 10.3390/cells8040366.

5.

Natural T cell autoreactivity to melanoma antigens: clonally expanded melanoma-antigen specific CD8 + memory T cells can be detected in healthy humans.

Przybyla A, Zhang T, Li R, Roen DR, Mackiewicz A, Lehmann PV.

Cancer Immunol Immunother. 2019 May;68(5):709-720. doi: 10.1007/s00262-018-02292-7. Epub 2019 Feb 19.

PMID:
30783693
6.
7.

The expression signature of cancer-associated KRAB-ZNF factors identified in TCGA pan-cancer transcriptomic data.

Machnik M, Cylwa R, Kiełczewski K, Biecek P, Liloglou T, Mackiewicz A, Oleksiewicz U.

Mol Oncol. 2019 Apr;13(4):701-724. doi: 10.1002/1878-0261.12407. Epub 2019 Feb 16.

8.

lncRNA Expression after Irradiation and Chemoexposure of HNSCC Cell Lines.

Guglas K, Kolenda T, Teresiak A, Kopczyńska M, Łasińska I, Mackiewicz J, Mackiewicz A, Lamperska K.

Noncoding RNA. 2018 Nov 14;4(4). pii: E33. doi: 10.3390/ncrna4040033.

9.

Whole cell melanoma vaccine genetically modified to stem cells like phenotype generates specific immune responses to ALDH1A1 and long-term survival in advanced melanoma patients.

Kwiatkowska-Borowczyk E, Czerwińska P, Mackiewicz J, Gryska K, Kazimierczak U, Tomela K, Przybyła A, Kozłowska AK, Galus Ł, Kwinta Ł, Dondajewska E, Gąbka-Buszek A, Żakowska M, Mackiewicz A.

Oncoimmunology. 2018 Aug 24;7(11):e1509821. doi: 10.1080/2162402X.2018.1509821. eCollection 2018.

10.

Optimization of spider silk sphere formation processing conditions to obtain carriers with controlled characteristics.

Florczak A, Jastrzebska K, Bialas W, Mackiewicz A, Dams-Kozlowska H.

J Biomed Mater Res A. 2018 Dec;106(12):3211-3221. doi: 10.1002/jbm.a.36516. Epub 2018 Sep 22.

PMID:
30242958
11.

Bioengineering the spider silk sequence to modify its affinity for drugs.

Kucharczyk K, Weiss M, Jastrzebska K, Luczak M, Ptak A, Kozak M, Mackiewicz A, Dams-Kozlowska H.

Int J Nanomedicine. 2018 Jul 20;13:4247-4261. doi: 10.2147/IJN.S168081. eCollection 2018.

12.

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients.

Mackiewicz J, Mackiewicz A.

Contemp Oncol (Pozn). 2018 Mar;22(1A):68-72. doi: 10.5114/wo.2018.73890. Epub 2018 Mar 5. Review.

13.

Oncogenic BRAF mutations and p16 expression in melanocytic nevi and melanoma in the Polish population.

Mackiewicz-Wysocka M, Czerwińska P, Filas V, Bogajewska E, Kubicka A, Przybyła A, Dondajewska E, Kolenda T, Marszałek A, Mackiewicz A.

Postepy Dermatol Alergol. 2017 Oct;34(5):490-498. doi: 10.5114/ada.2017.71119. Epub 2017 Oct 31.

14.

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

Maio M, Lewis K, Demidov L, Mandalà M, Bondarenko I, Ascierto PA, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Goodman GR, Simmons B, Ye C, Yan Y, Schadendorf D; BRIM8 Investigators.

Lancet Oncol. 2018 Apr;19(4):510-520. doi: 10.1016/S1470-2045(18)30106-2. Epub 2018 Feb 21. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.

PMID:
29477665
15.

Heterotypic breast cancer model based on a silk fibroin scaffold to study the tumor microenvironment.

Dondajewska E, Juzwa W, Mackiewicz A, Dams-Kozlowska H.

Oncotarget. 2017 Dec 22;9(4):4935-4950. doi: 10.18632/oncotarget.23574. eCollection 2018 Jan 12.

16.

Delivery of chemotherapeutics using spheres made of bioengineered spider silks derived from MaSp1 and MaSp2 proteins.

Jastrzebska K, Florczak A, Kucharczyk K, Lin Y, Wang Q, Mackiewicz A, Kaplan DL, Dams-Kozlowska H.

Nanomedicine (Lond). 2018 Feb;13(4):439-454. doi: 10.2217/nnm-2017-0276. Epub 2018 Jan 17.

17.

Wound fluids affect miR-21, miR-155 and miR-221 expression in breast cancer cell lines, and this effect is partially abrogated by intraoperative radiation therapy treatment.

Zaleska K, Przybyła A, Kulcenty K, Wichtowski M, Mackiewicz A, Suchorska W, Murawa D.

Oncol Lett. 2017 Oct;14(4):4029-4036. doi: 10.3892/ol.2017.6718. Epub 2017 Aug 3.

18.

TRIM28 epigenetic corepressor is indispensable for stable induced pluripotent stem cell formation.

Klimczak M, Czerwińska P, Mazurek S, Sozańska B, Biecek P, Mackiewicz A, Wiznerowicz M.

Stem Cell Res. 2017 Aug;23:163-172. doi: 10.1016/j.scr.2017.07.012. Epub 2017 Jul 15.

19.

Functionalized bioengineered spider silk spheres improve nuclease resistance and activity of oligonucleotide therapeutics providing a strategy for cancer treatment.

Kozlowska AK, Florczak A, Smialek M, Dondajewska E, Mackiewicz A, Kortylewski M, Dams-Kozlowska H.

Acta Biomater. 2017 Sep 1;59:221-233. doi: 10.1016/j.actbio.2017.07.014. Epub 2017 Jul 8.

20.

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.

Schadendorf D, Long GV, Stroiakovski D, Karaszewska B, Hauschild A, Levchenko E, Chiarion-Sileni V, Schachter J, Garbe C, Dutriaux C, Gogas H, Mandalà M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Grob JJ, Nathan P, Ribas A, Davies MA, Zhang Y, Kaper M, Mookerjee B, Legos JJ, Flaherty KT, Robert C.

Eur J Cancer. 2017 Sep;82:45-55. doi: 10.1016/j.ejca.2017.05.033. Epub 2017 Jun 22.

PMID:
28648698

Supplemental Content

Loading ...
Support Center